JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Retrospective evaluation of our patients diagnosed with advanced pancreatic cancer
Abstract
Aims: Pancreatic cancer attracts attention with its increasing frequency among gastrointestinal cancers. It has the worst prognosis of all cancer types. In this study, we aimed to retrospectively evaluate the clinical features and treatment results of our patients with advanced pancreatic cancer.
Methods: In this study, 131 patients diagnosed with advanced pancreatic cancer and admitted to the Ankara Numune Training and Research Hospital Medical Oncology Polyclinic between November 2002 and January 2014 were retrospectively analyzed. Demographic characteristics of the patients, smoking, family history, basal CEA and basal CA 19-9 levels, treatment modalities, metastasis sites, progression-free survival, and overall survival times were evaluated.
Results: The study population consisted of 131 patients, including 94 males and 37 females. Twenty of the patients were in the locally advanced stage, and 111 were in the metastatic stage. The median age of the patients was 60 years. 53.4% of the patients were smokers, and the median amount of smoking was 30 packs/year. Adenocancer was the most common histopathological subtype. The median basal CEA and Ca 19-9 levels were high at the time of diagnosis. Neoadjuvant chemotherapy was given to all locally advanced patients. The most commonly used chemotherapy regimens were single-agent gemcitabine and gemcitabine-cisplatin combination therapies. While 10 of the locally advanced patients received local treatment (chemotherapy or surgery) after neoadjuvant chemotherapy, the remaining 10 patients could not receive local treatment. The median overall and progression-free survival times were found to be significantly longer in patients with locally advanced disease who received local treatment after neoadjuvant chemotherapy [(18 months vs. 6.5 months; p=0.008), (11.3 months vs. 6.4 months; p=0.05)]. The most common site of metastasis in our patients with metastatic pancreatic cancer was the liver (80%). Cisplatin-gemcitabine was preferred as a KT regimen in 63.4% of metastatic cases. The median overall survival time of the patients in the metastatic stage was 8.1 months, and the median progression-free survival time was 5.7 months. The median progression-free survival of all patients included in the study was 6.2 months, while the median overall survival was 8.8 months.
Conclusion: The median overall survival of patients with locally advanced pancreatic cancer was significantly longer compared to metastatic patients (18 months vs. 8.1 months; p=0.028). Progression-free survival and overall survival of patients with locally advanced disease who received or did not receive local treatment after neoadjuvant chemotherapy were found to be significantly longer in patients who received local treatment. (11.3 months vs. 6.4 months; p=0.05) (18 months vs. 6.5 months; p=0.008). Response rates of patients with metastatic pancreatic cancer; It was 49% in the gemcitabine-cisplatin combination arm and 30% in the single-agent gemcitabine arm.

Keywords : Advanced pancreatic cancer, gemcitabine, cisplatin, survival

Download Article


1. Warshaw AL, Fernández-del Castillo C. Pancreatic carcinoma. N Engl JMed. 1992;326(7):455-465.
2. Ozkan H, Ozturk HJMB, Doktor. Pankreas kanserinde epidemiyoloji verisk faktorleri. MNKlinik Bilimler&Doktor. 2000;6(1):39-43.
3. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review,1975-2009 (vintage 2009 populations). 2012:1975-2009.
4. Von Hoff D. Chapter 79: Pancreatic cancer. Harrison’s Principles ofInternal Medicine, 20e. McGraw-Hill, New York, NY; 2018.
5. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primaryprognosticator for pancreatic cancer after regional pancreatectomy. AnnSurg. 1996;223(2):147-153
6. Li J, Merl MY, Chabot J, Saif MWJJJotP. Updates of adjuvant therapy inpancreatic cancer: where are we and where are we going? JOP. Journal of thePancreas. 2010;11(4):310-312.
7. Borgida AE, Ashamalla S, Al-Sukhni W, et al. Management of pancreaticadenocarcinoma in Ontario, Canada: a population-based study using novelcase ascertainment. Can J Surg. 2011;54(1):54-60.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluationcriteria in solid tumours: revised RECIST guideline (version 1.1). Eur JCancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
9. Hidalgo Pascual M, Ferrero Herrero E, Castillo Fé MJ, GuadarramaGonzález FJ, Peláez Torres P, Botella Ballesteros F. Epidemiology anddiagnosis of the pancreatic cancer. Rev Esp Enferm Dig. 2004;96(10):714-722
10. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG.Abeloff’s Clinical Oncology E-Book. Elsevier Health Sciences; 2008.
11. Nöthlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LNJTAjocn.Dietary glycemic load, added sugars, and carbohydrates as risk factors forpancreatic cancer: the Multiethnic Cohort Study. The American journal ofclinical nutrition. 2007;86(5):1495-1501.
12. Tuncer AM, Özgül N, Olcayto E, Gültekin MJTSBKSDB, Ankara.Türkiye’de kanser kontrolü. 2009.
13. Mills S, Carter D, Greenson J, Oberman H, Reuter V, Stoler M. Sternberg’sdiagnostic surgical pathology.: Lippincott Williams-Wilkins. Philadelphia;2004.
14. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors forpancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):197-209.
15. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the riskof pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg.2008;393(4):535-545.
16. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independentrisk factor for cancer?. Exp Clin Endocrinol Diabetes. 2010;118(1):4-8.
17. Gullo L, Pezzilli R, Morselli-Labate AM; Italian Pancreatic CancerStudy Group. Diabetes and the risk of pancreatic cancer. N Engl J Med.1994;331(2):81-84.
18. Buxbaum JL, Eloubeidi MA. Molecular and clinical markers of pancreascancer. JOP. 2010;11(6):536-544.
19. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreaticcancer. Jpn J Clin Oncol. 2004;34(5):238-244.
20. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrateantigen (CA 19-9) as a biochemical marker in the diagnosis of pancreaticcancer. Eur J Surg Oncol. 2007;33(3):266-270
21. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9,and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J SurgOncol. 2005;31(2):164-169.
22. Tsavaris N, Tsigritis K, et al. Evaluation of DNA ploidy in relationwith established prognostic factors in patients with locally advanced(unresectable) or metastatic pancreatic adenocarcinoma: a retrospectiveanalysis. BMC cancer. 2009;9(1):1-11.
23. Trikudanathan G, Dasanu CAJSMJ. Adenosquamous carcinoma of thepancreas: a distinct clinicopathologic entity. Southern Medical Journal2010;103(9):903-910.
24. Gupta S, Wang F, Holly EA, Bracci PMJCC, Control. Risk of pancreaticcancer by alcohol dose, duration, and pattern of consumption, includingbinge drinking: a population-based study. Cancer Causes & Control2010;21(7):1047-1059.
25. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patientswith locally advanced, unresectable pancreatic cancer for optimal benefit fromconsolidative chemoradiation therapy. Cancer. 2007;110(1):47-55.
26. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapyafter disease control with chemotherapy in locally advanced pancreaticadenocarcinoma in GERCOR phase II and III studies. J of Clin Oncol.2007;25(3):326-331.
27. El Kamar FG, Grossbard ML, Kozuch PSJTo. Metastatic pancreaticcancer: emerging strategies in chemotherapy and palliative care. Theoncologist. 2003;8(1):18-34.
28. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or withcisplatin for the treatment of patients with locally advanced and/ormetastatic pancreatic carcinoma: A prospective, randomized phaseIII study of the Gruppo Oncologico dell’Italia Meridionale. Cancer.2002;94(4):902-910.
29. Inal A, Kos F, Algin E, et al. Gemcitabine alone versus combinationof gemcitabine and cisplatin for the treatment of patients with locallyadvanced and/or metastatic pancreatic carcinoma: a retrospectiveanalysis of multicenter study. Neoplasma. 2012;59(3):297-301
Article available in :
Volume 1, Issue 3, 2023
Page : 49-53
https://doi.org/10.51271/JCHOR-0012
Article Information
Received : 01 Aug 2023
Accepted : 23 Aug 2023
Published : 30 Aug 2023
Corresponding Author :

Zeynep Tuğba Karabulut: Department of Hematology, Adana City Training and Research Hospital, Adana, Turkiye

[email protected]
Citation : Güven ZT, Karaahmetoğlu S, Doğan M. Retrospective evaluation of our patients diagnosed with advanced pancreatic cancer. J Curr Hematol Oncol Res. 2023;1(3):49-53.

Read: 393
Download : 858
Cited: 0
_Footer